Dynamics of Erythropoietic Biomarkers in Response to Treatment With Erythropoietin in Belgrade Rats
Open Access
- 10 April 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 9, 316
Abstract
Recombinant human erythropoietin (rHuEPO) is used effectively in the treatment of various anemic disorders. Belgrade rat is a useful animal model of anemia caused by defect in iron utilization. The objective of the present study was to investigate the dynamics of erythropoietic biomarkers in Belgrade rats receiving rHuEPO. Pharmacokinetics of rHuEPO was evaluated in Belgrade rats and normal rats after intravenous administration of single doses of the drug (100 and 1350 IU/kg). Pharmacodynamic biomarkers included levels of red blood cells, hemoglobin, and reticulocytes following administration of a single intravenous dose of rHuEPO (100 IU/kg). Red blood cell survival was assessed after treatment with rHuEPO (450 IU/kg), three times a week for 2 weeks. It was found that rHuEPO exhibited non-linear pharmacokinetics in both Belgrade and control rats. At the low dose, plasma concentrations and AUC (area under the curve) were significantly lower while clearance and volume of distribution were higher in Belgrade rats (p < 0.05). At the higher dose, there was no difference in pharmacokinetics between the two groups. Erythropoietic effect of rHuEPO was negligible in Belgrade rats at the dose of 100 IU/kg whereas all studied erythropoietic biomarkers were increased in normal rats. The levels of red blood cells, hemoglobin were significantly lower whereas the percentage of reticulocytes was higher in Belgrade rats compared to that in normal rats (p < 0.05). RHuEPO increased red blood cell survival in both animal groups. In conclusion, rHuEPO effect on erythropoietic biomarkers was stronger in normal rats than Belgrade rats at the studied doses. The findings from this study may provide further insights into understanding of anemic disorders resulting from mutations in the divalent metal transporter.Keywords
This publication has 32 references indexed in Scilit:
- A novel N491S mutation in the human SLC11A2 gene impairs protein trafficking and in association with the G212V mutation leads to microcytic anemia and liver iron overloadBlood Cells, Molecules, and Diseases, 2011
- Simultaneous Pharmacokinetics/Pharmacodynamics Modeling of Recombinant Human Erythropoietin upon Multiple Intravenous Dosing in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Erythropoietins: A common mechanism of actionExperimental Hematology, 2008
- Natural History of Recessive Inheritance of DMT1 MutationsThe Journal of Pediatrics, 2008
- Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Administration in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjectsEuropean Journal of Pharmaceutical Sciences, 2005
- Kinetic Evaluation of Nonlinear Drug Elimination by a Disposition Decomposition Analysis. Application to the Analysis of the Nonlinear Elimination Kinetics of Erythropoietin in Adult HumansJournal of Pharmaceutical Sciences, 1995
- Biotin labeling as an alternative nonradioactive approach to determination of red cell survivalAnnals of Hematology, 1993
- Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cellsJournal of Cellular Physiology, 1988
- Purification of human erythroid colony-forming units and demonstration of specific binding of erythropoietin.Journal of Clinical Investigation, 1987